| INTRODUC TI ON
Multiple myeloma (MM) is the second most common hematological malignancy and is characterized by accumulation of malignant plasma cells within the bone marrow.
1 Multiple myeloma is largely incurable and relapse eventually occurs because it is difficult to eradicate all myeloma cells, despite the recent development of novel therapies. 2 This incurable feature is mainly attributed to a remaining population of drug-resistant cancer stem cells. 3, 4 Side population (SP) cells are identified in a flow cytometry plot with weak staining of Hoechst 33342 as a result of their high expression of an ATP-binding cassette (ABC) membrane transporter that exports this dye. [5] [6] [7] [8] Side population cells in MM are known to be enriched with myeloma stem cells featured by repopulation, selfrenewal, differentiation, and clonogenicity abilities. 9, 10 Therefore, targeting SP cells can be a promising strategy to prevent and treat MM relapse.
Polycomb repressive complex 2 (PRC2), a member of the polycomb group of protein complexes, is an important epigenetic regulator that maintains the "stemness" of embryonic and hematopoietic stem cells. [11] [12] [13] [14] [15] [16] [17] [18] Enhancer of zeste homolog 1 and 2 (EZH1/2) are catalytic components of PRC2 that trimethylate histone H3 at lysine 27 (H3K27me3) to repress transcription of its target genes. Mutation or overexpression of EZH2 is associated with tumorigenesis or tumor progression in many cancer types, including MM. 10, [19] [20] [21] [22] [23] [24] [25] Indeed, increased silencing of H3K27me3 targets was reported in MM patients at advanced stages of the disease, and the expression pattern of H3K27me3-marked genes correlates with poor patient survival. 21, 26 These results suggest that overexpression of EZH2 is responsible for tumor progression and that EZH2 is a potential therapeutic target in MM. Indeed, selective EZH2 inhibitors have been developed and some of them are currently being investigated in clinical trials against various malignant tumors, including MM. [26] [27] [28] [29] Furthermore, upregulation of EZH2 in SP cells has been reported and this suggests that EZH2
has an important role for stem cell maintenance in MM. 10 However, it remains unclear whether EZH1, the other catalytic subunit of PRC2, is important to maintain the stemness of MM cells, although EZH1 only partially compensates for loss of EZH2 in stem cell maintenance. [30] [31] [32] Our group recently discovered that EZH1 complements EZH2 and that dual inactivation of EZH1/2 depletes quiescent leukemia stem cells to cure acute myeloid leukemia. 33 Therefore, we hypothesized that EZH1, in addition to EZH2, is also important for stem cell maintenance in MM and that dual inhibition of EZH1/2 could eradicate myeloma stem cells as seen in acute myeloid leukemia. Here, we used a novel orally bioavailable EZH1/2 dual inhibitor, OR-S1, which potently inhibits both EZH1 and EZH2. 34 This translational tool enabled us to investigate the role of EZH1/2 in myeloma stem cells by analyzing SP cells.
The present study aimed to investigate the function of EZH1/2 in the maintenance of myeloma stem cells and to evaluate whether dual inhibition of EZH1/2 can be an effective therapeutic approach to eradicate myeloma stem cells.
| MATERIAL S AND ME THODS

| Compounds
GSK126 was generated as previously described. 35 The synthesis and characterization of OR-S1 (Daiichi Sankyo, Tokyo, Japan) are described in a Patent Cooperation Treaty application (publication number: WO2015/141616).
| In vivo xenograft studies
NOD/ShiJic-scidJcl (NOD-SCID) mice were purchased from CLEA Japan (Tokyo, Japan 
| Patient-derived xenograft model
Human MM samples were obtained from patients at Tokyo Medical and Dental University or National Cancer Center Hospital. All patients provided informed consent, and the study was approved by 
| Statistical analyses
Statistical significance was determined using Student's t test or an analysis of variance after testing whether the data were normally Full methods and any associated references are available in Data S1.
| RE SULTS
| Expression of EZH1 and EZH2 is significantly increased in SP cells
We first examined the proportion of SP cells in human myeloma cell 
| OR-S1 depletes myeloma stem cells and impairs proliferation of all MM cell lines
To investigate the effect of pharmacological inhibition of EZH1/2 on MM, we used a novel orally bioavailable EZH1/2 dual inhibitor, OR-S1, which is a histone methyltransferase inhibitor with high selectivity for both EZH1 and EZH2 ( Figure   S1A ). 34 We first investigated whether OR-S1 reduces the level ( Figure 2D ). Multiple myeloma cell lines were also highly sensitive to OR-S1 in a growth inhibition assay; OR-S1 inhibited the growth of all MM cell lines tested in a dose-dependent method, and its half maximal growth inhibition (GI 50 ) values were significantly lower than those of the EZH2-specific inhibitor GSK126
(Figures 2E and S1E, and Table S1 ). 35 OR-S1 also suppressed the proliferation of KMS-11/BTZ cells (GI 50 = 3.6 nmol/L), which are resistant to bortezomib as a result of mutation of PSMB5, 36 whereas GSK126 did not impair the proliferation of these cells (GI 50 = 692.3 nmol/L). These results suggest that OR-S1 is effective in all MM cell lines and that dual inhibition of EZH1/2 by OR-S1 eradicates myeloma stem cells.
| Dual inhibition of EZH1/2 overactivates WNT signaling by reducing the level of H3K27me3
To examine the molecular mechanism by which OR-S1 regulates the proliferation of MM cells, we carried out RNA sequencing (RNA-seq) of MM.1S and RPMI8226 cells. OR-S1 treatment significantly upregulated 421 pathways in both cell lines ( Figure 3A ). Transcriptional profiles of OR-S1-treated MM cell lines were characterized by upregulation of genes related to the WNT, cell cycle, cell differentiation, apoptosis, and RANKL-RANK pathways ( Figures 3B,C and S2A,B). We next carried out ChIP-sequencing using MM cell
Dual inhibition of enhancer of zeste homolog 1/2 (EZH1/2) overactivates WNT signaling by reducing the level of trimethylated histone H3 at lysine 27 (H3K27me3 Figures 3D and S2C ). Treatment with 1 μmol/L OR-S1
for 3 days upregulated many WNT and FZD genes >1.5-fold, and a peak of H3K27me3 at these loci was detected by model-based analysis of ChIP-seq (peak score >10, ±10 kb from transcription start site; Tables S2 and S3 ). These results suggest that direct crosstalk occurs between PRC2 and WNT signaling, and we therefore focused on this pathway. RT-PCR confirmed that OR-S1 treatment markedly increased expression of WNT and FZD family members more than GSK126 treatment ( Figure 4A ). In addition, western blot analysis showed that non-phosphorylated (active) β-catenin was strongly expressed and expression of genes downstream of β-catenin was significantly upregulated in OR-S1-treated cells ( Figures 4B and S2D ).
Furthermore, ChIP-qPCR analysis showed that OR-S1 treatment markedly decreased the level of H3K27me3 at most WNT and FZD loci ( Figure 4C ). These results indicate that PRC2 directly targets WNT signaling and that dual inhibition of EZH1/2 by OR-S1 activates WNT/β-catenin signaling.
| Repression of WNT signaling by PRC2 is important to maintain the stemness of MM cells
Increased activation of the WNT/β-catenin signaling pathway is reportedly related to decreased self-renewal and differentiation of hematopoietic stem cells. 37 
| Oral administration of OR-S1 completely cures MM in mouse xenograft models
Because OR-S1 inhibited the growth of all MM cell lines tested in vitro, we next examined its effect on these cells in vivo. Oral Figure S1C) . Similarly, the survival assay showed that all OR-S1-treated mice with MM.1S orthotopic xenografts eventually died as a result of disease progression, even though oral dosage of OR-S1 for 3 weeks markedly prolonged their survival time ( Figure   S3E ). Our results showed that myeloma stem cells were specifically sensitive to dual inhibition of EZH1/2; therefore, we hypothesized that continuous dosage of OR-S1 would cure mice with 
| OR-S1 reduces myeloma cells in a patientderived xenograft model developed using primary MM samples
It is difficult to establish patient-derived xenograft (PDX) models by subcutaneous or venous injection of primary MM samples because the bone marrow niche is considered to be crucial for the engraftment or homing of MM cells. 38, 39 Thus, we exploited tibial intramedullary injection to develop an orthotopic PDX model using a sample of a relapsed patient pretreated with various drugs, including bortezomib (the patient's background is provided in Table   S4 ). Engraftment was confirmed by detecting human immunoglobulins in the serum of mice, as carried out at the clinical bedside. 40, 41 Serum levels of human immunoglobulins were measured monthly to evaluate tumor progression or therapeutic effects ( Figure 7A ).
OR-S1 was orally given for 2 months after human IgG was clearly detected in serum. OR-S1 markedly suppressed the increases in human immunoglobulin levels in this PDX model, whereas these levels gradually increased in non-treated mice ( Figure 7B ). Flow cytometric analysis showed that the percentage of hCD38 + cells within the bone marrow was markedly reduced in OR-S1-treated mice at the final follow up ( Figure 7C ). Furthermore, RT-PCR confirmed that OR-S1 treatment significantly increased expression of WNT and FZD family members in this model, as seen in the MM cell lines ( Figure 7D ). These results indicate that targeting EZH1/2 with OR-S1 is also effective against MM in a PDX model.
| D ISCUSS I ON
This study investigated the role of EZH1/2 in the maintenance of myeloma stem cells by using a novel EZH1/2 dual inhibitor, OR-S1.
Expression of EZH1 and EZH2 was significantly increased in the SP fraction of MM cells, and repression of WNT signaling, a direct target of PRC2, was important to maintain the stemness of myeloma stem cells. Furthermore, OR-S1 impaired the self-renewal activity of myeloma stem cells.
Enhancer of zeste homolog 2 has oncogenic activity in MM
22
and the expression level of EZH2 is significantly increased in SP cells. 10 This suggests that inhibition of EZH2 could be a stem celltargeted therapy in MM treatment, because SP cells have stem-like characteristics in MM. 9, 10 However, it has been reported that inhibition of EZH2 alone does not completely disrupt PRC2 function and that EZH1/2 dual inhibition is crucial to treat other hematological malignancies, such as acute myeloid leukemia and malignant lymphoma. 33, 42 Although UNC1999, an EZH1/2 dual inhibitor, also inhibits the growth of myeloma cells, 43 it is unclear whether EZH1
plays an important role in stem cell maintenance in MM. Here, we
showed that the expression of EZH1, as well as EZH2, was significantly increased in the SP fraction of MM cells, suggesting that inhibition of EZH1, in addition to EZH2, is necessary to eradicate myeloma stem cells when targeting PRC2. As expected, dual inhibition of EZH1/2 using OR-S1 depleted myeloma stem cells in vitro and in vivo. Additionally, giving long-term continuous OR-S1 completely cured these mice without eliciting any serious side-effects, suggesting that myeloma stem cells are specifically susceptible to dual inhibition of EZH1/2 and lose their self-renewal activity when continuously exposed to OR-S1. Therefore, continuous administration of OR-S1 would be an effective treatment option against some types of MM cells that do not show OR-S1-induced apoptosis, such as MM.1S cells.
Our results also showed that there is direct crosstalk between PRC2 and WNT signaling in MM, which has also been reported in PRC2-mediated differentiation of chondrocytes and adipocytes. 44, 45 Most WNT and FZD genes were repressed by H3K27me3, and re- 
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This difference would be one of the reasons why OR-S1 showed better growth inhibition efficacy than other inhibitors. These results indicate that inhibition not only of EZH2 but also of EZH1 is crucial to successfully treat myeloma. Additionally, lower doses of OR-S1 suppressed the proliferation of KMS-11/BTZ cells, which are known to be resistant to bortezomib as a result of the mutation of PSMB5. 36, 49 This mutation was also recently reported in a bortezomib-resistant MM patient. 50 Although proteasome inhibitors are key drugs in MM therapy, patients eventually develop drug resistance upon prolonged treatment. Thus, OR-S1 may have significant advantages for the treatment of relapsed MM because its mechanism of action is completely separate from that of proteasome inhibitors. Although PRC2 is known to be an important molecule for stemness maintenance in hematopoietic stem cells, our group previously showed that OR-S1
does not cause significant myelosuppression even after 4 months of treatment. 33 In this study, neither abnormal clinical signs nor significant body weight loss was observed in mice throughout longterm continuous administration of OR-S1 for 150 days; therefore, long-term continuous administration would be a clinically feasible regimen. 34, 51 This favorable safety profile has enabled us to move forward to clinical trials as the only clinically applicable EZH1/2 inhibitor; 29 subsequently evaluating the effect of OR-S1 against MM patients would be encouraged as a novel therapeutic option for relapsed MM.
In summary, our results strongly suggest that repression of WNT signaling by EZH1/2 is important to maintain the stemness of MM cells and that dual inhibition of EZH1/2 with OR-S1 is a promising therapeutic approach to eradicate myeloma stem cells, leading to significant advances in the treatment of MM.
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Issay Kitabayashi http://orcid.org/0000-0002-8409-0407 F I G U R E 7 Translational implication of enhancer of zeste homolog 1/2 (EZH1/2) dual inhibition in multiple myeloma (MM). A, Experimental schema showing how successful engraftment was confirmed. Levels of human immunoglobulins in the serum of mice were measured 1 mo after intramedullary injection of clinical samples. NOG, NOD.Cg-Prkdcscid Il2rgtm1Sug/Jic (Central Institute for Experimental Animals, Kawasaki, Japan). B, Bar graph showing the levels of human IgG in the serum of control and OR-S1-treated engrafted mice. Treatment with OR-S1 (400 mg/kg per day orally for 60 d) was started 2 mo after transplantation, and levels of human IgG were monitored monthly (n = 4 per group). Error bars represent the mean ± SD. *P < .05. C, Representative FACS plots and a bar graph showing the percentage of hCD38 + cells within the bone marrow of control and OR-S1-treated mice with patient-derived xenograft (PDX) at the final follow up. Error bars represent the mean ± SD. *P < .00001 (Student's t test). D, RT-PCR analysis showing relative expression of WNT-related genes in myeloma cells in a PDX model. Mice were given 400 mg/kg per day OR-S1 orally for 3 wk following engraftment of tumors. Y-axis represents the fold-change in gene expression after normalization to that of ACTB. Error bars represent the mean ± SD. *P < .05; **P < .01; ***P < .001 (Student's t test)
